---
document_datetime: 2025-09-24 10:20:18
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/stoboclo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: stoboclo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.380131
conversion_datetime: 2025-12-30 22:37:53.039346
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Stoboclo

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | C.I.2 Change(s) in the Summary of Product | 19/09/2025                          |                                             | SmPC, Annex                      |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000291992                     | Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a - to update section 5.1 of the SmPC following the adoption of the same changes for the reference product, Prolia (case no. EMA/VR/0000267398). Editorial changes introduced in the Prolia PI, which are equally applicable to the Stoboclo PI, have likewise been implemented throughout. In addition, the MAH has taken this opportunity to introduce editorial updates to the Stoboclo PI, including rewording of the storage period at room temperature, revision of the address format and correction of grammatical and   |            |     | II, Labelling and PL   |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------|
| Article 61(3) / EMA/N/0000295849      | - Notification acc. Article 61(3) - Accepted Update of the package leaflet with revised details of local representatives.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 15/09/2025 |     | PL                     |
| Variation type IB / EMA/VR/0000268596 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 04/09/2025 | N/A |                        |

<div style=\"page-break-after: always\"></div>

|                                       | B.I.b) Control of active substance - B.I.b.z Other variation - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |     |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000265206 | B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.a Replacement or addition of a site where batch control/testing takes place - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 03/07/2025 | N/A |
| Variation type II / EMA/VR/0000255109 | This was an application for a group of variations. B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.b Replacement or addition of a site where batch control/testing takes place for a biological/immunological product and any of the test methods performed at the site is a biological/immunological method - Accepted B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.c Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for biological/ immunological medicinal products, or for pharmaceutical forms manufactured by | 12/06/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                                  | complex manufacturing processes - Accepted   |            |    |
|----------------------------------|----------------------------------------------|------------|----|
| Article 61(3) / EMA/N/0000266444 | - Notification acc. Article 61(3) - Accepted | 02/05/2025 | PL |